Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:08:04.339Z.
Calculation as of: 2026-10-06T19:08:04.339Z.
Quote observation: 2026-10-06T19:04:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 196692da0c380a40ac90dfab7941532e3601431322d0ea6e9ae3bdc8429e964f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$90.20M
EV/EBITDA Ratio
15.00x
TTM Avg
15.77x
3Y Avg
20.95x
5Y Avg
32.73x
Market Cap
$88.84M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rallybio Corporation (RLYB) | $90.11M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 15.00x | 15.77x | 20.95x | 32.73x |
| electroCore, Inc. (ECOR)vs › | $89.89M | N/A | N/A | N/A | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.60M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $89.45M | 4.73x | 4.46x | 3.36x | 3.41x |
| Biomea Fusion, Inc. (BMEA)vs › | $90.74M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $91.78M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $91.07M | N/A | N/A | N/A | N/A |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $88.84M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $94.32M | N/A | 51.11x | 51.11x | 51.11x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
